TRITON3: A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency (protocol CO-338-063)
The purpose of this study is to find out how effective the study drug, rucaparib, is on advanced prostate cancer in men with DNA-Repair anomalies and to find out the side effects of the study drug. Rucaparib is currently FDA approved in advanced ovarian cancer, but not for prostate cancer.
Metastatic Castration Resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer
- Previous therapy with at least one prior next-generation AR-targeted therapy for castration-resistant disease (such as: abiraterone acetate, enzalutamide, or investigational AR-targeted agent)
- Eligible for treatment with physician’s choice of comparator treatment, selected prior to randomization (abiraterone acetate, enzalutamide, or docetaxel)
- DNA-repair anomalies (to be tested as a part of the screening process)
- No prior treatments with a PARP inhibitor or a platinum containing chemotherapy regimen
18 - 100
Healthy Volunteers Needed
Duration of Participation
Up to 24 months
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Clovis Oncology, Inc.